U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 211 - 220 of 463 results

Status:
Possibly Marketed Outside US
Source:
FLUIDBASE AHA 10 by LABORATORIO GENOVE S.A.
(2016)
Source URL:

Class:
POLYMER

Status:
Possibly Marketed Outside US
Source:
Japan:Cellulose Acetate Phthalate
Source URL:

Class:
POLYMER

Cellacefate is a commonly used polymer phthalate in the formulation of pharmaceuticals, such as the enteric coating of tablets or capsules and for controlled release formulations. Cellacefate's use in enteric coatings allows tablets to remain intact in the unfavorable gastric acid secretion of the stomach, but dissolve in the more basic areas of the duodenum, thus protecting the stomach from ulceration or allowing greater absorption form the duodenum. Cellacefate is a reaction product of phthalic anhydride and a partial acetate ester of cellulose.
structurally diverse
Status:
US Approved OTC
Source:
21 CFR 349.14(b)(4) ophthalmic:emollient petrolatum
Source URL:
First marketed in 1921
Source:
Petrolatum U.S.P.
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
US Approved OTC
Source:
21 CFR 349.14(b)(3) ophthalmic:emollient paraffin
Source URL:
First marketed in 1921
Source:
Paraffin U.S.P.
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
US Approved OTC
Source:
21 CFR 349.14(a)(2) ophthalmic:emollient lanolin (in combination)
Source URL:
First marketed in 1921
Source:
Hydrous Wool Fat U.S.P.
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
US Approved Allergenic Extract (1967)
First marketed in 1921

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
US Previously Marketed
Source:
21 CFR 310.545(a)(8)(ii) digestive aid senna
Source URL:

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
US Previously Marketed
Source:
21 CFR 310.545(a)(12)(iv)(A) laxative:stimulant laxative podophyllum resin (podophyllin)
Source URL:
First approved in 1990

Class:
STRUCTURALLY DIVERSE


Podophyllum resin is the powdered mixture of resins removed from the May apple or Mandrake, a perennial plant of the northern and middle United States. The early colonists learned of themedical properties of the root from the Indians, and it was used as a cathartic in the firstUnited States Pharmacopoeia (1820). The resin, podophyllin, was first separated from Podophyllum by John King in 1835. Between 1863 and 1942, podophyllin was reported to be a cathartic, purgative, deobstruent, vermifuge, hydragogue, cholagogue, choleretic, andexpectorant.Itwas recommended, either alone or in combination with other herbs, for diseases of the liverandkidneys, for scrofula, syphilis, gonorrhea, obstructed menstruation, urinary obstruction, dropsy, and coughs. Currently Podophyllum resin is used as a medication to treat genital warts and plantar warts, including in people with HIV/AIDS. Common side effects include redness, itchiness, and pain at the site of use. Severe side effects may include vomiting, abdominal pain, confusion, bone marrow suppression, and diarrhea. It is not recommended for more than a small area at a time. Use during pregnancy is known to be dangerous to the baby.
structurally diverse
Status:
US Previously Marketed
Source:
Ipecac U.S.P.
(1921)
Source URL:
First marketed in 1921

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Possibly Marketed Outside US
Source:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/ucm071835.htm laxative:stimulant laxative senna pod concentrate
Source URL:
First approved in 2019

Class:
STRUCTURALLY DIVERSE

Showing 211 - 220 of 463 results